K
Klaus Pantel
Researcher at University of Hamburg
Publications - 566
Citations - 36666
Klaus Pantel is an academic researcher from University of Hamburg. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 90, co-authored 486 publications receiving 29848 citations.
Papers
More filters
Journal ArticleDOI
Liquid biopsy and minimal residual disease - latest advances and implications for cure.
TL;DR: Assays based on the detection of small numbers of circulating tumour cells or minute amounts of circulating cell-free tumour DNA (ctDNA) now enable MRD detection in patients with various malignancies and can provide insights into the molecular evolution of MRD during tumour progression.
Journal ArticleDOI
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors
Xin Lu,Euphemia Mu,Yong Wei,Sabine Riethdorf,Qifeng Yang,Qifeng Yang,Min Yuan,Jun Yan,Yuling Hua,Benjamin Tiede,Xuemin Lu,Bruce G. Haffty,Klaus Pantel,Joan Massagué,Yibin Kang,Yibin Kang +15 more
TL;DR: A bone metastasis dormancy model is characterized to show that aberrant expression of vascular cell adhesion molecule 1 (VCAM-1), in part dependent on the activity of the NF-κB pathway, promotes the transition from indolent micrometastasis to overt metastasis.
Journal ArticleDOI
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
TL;DR: This pilot study provides first evidence that tumor-associated circulating miRs are elevated in the blood of breast cancer patients and associated with tumor progression.
Journal ArticleDOI
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.
TL;DR: Findings relating to the interactions of CTCs and DTCs with the immune system are discussed, in the context of cancer immuno-editing, evasion from immune surveillance, and formation of metastases.
Journal ArticleDOI
Liquid Biopsies, What We Do Not Know (Yet).
Alberto Bardelli,Klaus Pantel +1 more
TL;DR: The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated and open questions in this fast-evolving field of research are addressed.